Epoxide-mediated CifR repression of cif gene expression utilizes two binding sites in Pseudomonas aeruginosa

Journal of Bacteriology

Volumn 194, Issue 19, 2012, Pages 5315-5324

  Ballok, Alicia E ^a   Bahl, Christopher D ^a   Dolben, Emily L ^a   Lindsay, Allia K ^a   St Laurent, Jessica D ^a   Hogan, Deborah A ^a   Madden, Dean R ^a   O'Toole, George A ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; EPOXIDE; MEMBRANE PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR INHIBITOR FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BACTERIUM ISOLATE; BINDING AFFINITY; BINDING SITE; BIOTINYLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA BINDING; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MUTAGENESIS; OPERON; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA;

BACTERIAL PROTEINS; BINDING SITES; CLONING, MOLECULAR; CYSTIC FIBROSIS; DNA, BACTERIAL; DNA, INTERGENIC; EPOXY COMPOUNDS; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; MUTAGENESIS; MUTATION; OPERON; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; VIRULENCE FACTORS;

PSEUDOMONAS AERUGINOSA;

EID: 84868311037     PISSN: 00219193     EISSN: 10985530     Source Type: Journal    
DOI: 10.1128/JB.00984-12     Document Type: Article

References (44)

1. Bahl CD, MacEachran DP, O'Toole GA, Madden DR. 2010. Purification, crystallization, and preliminary X-ray diffraction analysis of Cif, a virulence factor secreted by Pseudomonas aeruginosa. Acta Crystallogr. Sect. F Struct. Biol. Crystallogr. Commun. 66:26-28.
2. Bahl CD, Madden DR. 2012. Pseudomonas aeruginosa Cif defines a distinct class of alpha/beta epoxide hydrolases utilizing a His/Tyr ringopening pair. Protein Pept. Lett. 19:186-193.
3. Bahl CD, et al. 2010. Crystal structure of the cystic fibrosis transmembrane conductance regulator inhibitory factor Cif reveals novel active-site features of an epoxide hydrolase virulence factor. J. Bacteriol. 192:1785-1795.
4. Baucheron S, et al. 2012. Binding of the RamR repressor to wild-type and mutated promoters of the RamA gene involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. Antimicrob. Agents Chemother. 56:942-948.
5. Behrends V, et al. Metabolic adaptations of Pseudomonas aeruginosa during cystic fibrosis chronic lung infections. Environ. Microbiol., in press.
6. Bendiak GN, Ratjen F. 2009. The approach to Pseudomonas aeruginosa in cystic fibrosis. Semin. Respir. Crit. Care Med. 30:587-595.
7. Bomberger JM, et al. 2009. Long-distance delivery of bacterial virulence factors by Pseudomonas aeruginosa outer membrane vesicles. PLoS Pathog. 5:e1000382. doi:10.1371/journal.ppat.1000382.
8. Bomberger JM, et al. 2010. A Pseudomonas aeruginosa toxin that hijacks the host ubiquitin proteolytic system. PLoS Pathog. 7:e1001325. doi: 10.1371/journal.ppat.1001325.
9. Boucher RC. 2007. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu. Rev. Med. 58:157-170.
10. Caiazza NC, O'Toole GA. 2004. SadB is required for the transition from reversible to irreversible attachment during biofilm formation by Pseudomonas aeruginosa PA14. J. Bacteriol. 186:4476-4485.
11. Ciofu O, Mandsberg LF, Bjarnsholt T, Wassermann T, Hoiby N. 2010. Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology 156:1108-1119.
12. Ciofu O, Riis B, Pressler T, Poulsen HE, Hoiby N. 2005. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob. Agents Chemother. 49:2276-2282.
13. D'Argenio DA, et al. 2007. Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients. Mol. Microbiol. 64:512-533.
14. Harrison F. 2007. Microbial ecology of the cystic fibrosis lung. Microbiology 153:917-923.
15. Hazlett LD. 2004. Corneal response to Pseudomonas aeruginosa infection. Prog. Retin. Eye Res. 23:1-30.
16. Hogardt M, Heesemann J. 2012. Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. Int. J. Med. Microbiol. 300: 557-562.
17. Hogardt M, Heesemann J. 2012. Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung. Curr. Top. Microbiol. Immunol. [Epub ahead of print.] doi:10.1007/82_2011_199.
18. Kadurugamuwa JL, Beveridge TJ. 1997. Natural release of virulence factors in membrane vesicles by Pseudomonas aeruginosa and the effect of aminoglycoside antibiotics on their release. J. Antimicrob. Chemother. 40:615-621.
19. Kerr KG, Snelling AM. 2009. Pseudomonas aeruginosa: a formidable and ever-present adversary. J. Hosp. Infect. 73:338-344.
20. Ko YH, Pedersen PL. 2001. Cystic fibrosis: a brief look at some highlights of a decade of research focused on elucidating and correcting the molecular basis of the disease. J. Bioenerg. Biomembr. 33:513-521.
21. Kuchma SL, et al. 2010. c-di-GMP-mediated repression of swarming motility by Pseudomonas aeruginosa: the pilY1 gene and its impact on surface-associated behaviors. J. Bacteriol. 92:2950-2964.
22. Lau GW, Hassett DJ, Ran H, Kong F. 2004. The role of pyocyanin in Pseudomonas aeruginosa infection. Trends Mol. Med. 10:599-606.
23. Li M, et al. 2007. Crystal structure of the transcriptional regulator AcrR from Escherichia coli. J. Mol. Biol. 374:591-603.
24. Li Y, Jiang Z, Chen H, Ma WJ. 2004. A modified quantitative EMSA and its application in the study of RNA-protein interactions. J. Biochem. Biophys. Methods 60:85-96.
25. MacEachran DP, Stanton BA, O'Toole GA. 2008. Cif is negatively regulated by the TetR family repressor CifR. Infect. Immun. 76:3197-3206.
26. MacEachran DP, et al. 2007. The Pseudomonas aeruginosa secreted protein PA2934 decreases apical membrane expression of the cystic fibrosis transmembrane conductance regulator. Infect. Immun. 75:3902-3912.
27. Maniatis T, Sambrook J, Fritsch EF. 1989. Molecular cloning: a laboratory manual, 2nd ed. CSHL Press, Cold Spring Harbor, NY.
28. Mathee K, et al. 2008. Dynamics of Pseudomonas aeruginosa genome evolution. Proc. Natl. Acad. Sci. U. S. A. 105:3100-3105.
29. Mena KD, Gerba CP. 2009. Risk assessment of Pseudomonas aeruginosa in water. Rev. Environ. Contam. Toxicol. 201:71-115.
30. Mittal R, Aggarwal S, Sharma S, Chhibber S, Harjai K. 2009. Urinary tract infections caused by Pseudomonas aeruginosa: a minireview. J. Infect. Public Health 2:101-111.
31. Orth P, Schnappinger D, Hillen W, Saenger W, Hinrichs W. 2000. Structural basis of gene regulation by the tetracycline inducible Tet repressor-operator system. Nat. Struct. Biol. 7:215-219.
32. Rahme LG, et al. 1995. Common virulence factors for bacterial pathogenicity in plants and animals. Science 268:1899-1902.
33. Ramos JL, et al. 2005. The TetR family of transcriptional repressors. Microbiol. Mol. Biol. Rev. 69:326-356.
34. Rodriguez-Rojas A, Oliver A, Blazquez J. Intrinsic and environmental mutagenesis drive diversification and persistence of Pseudomonas aeruginosa in chronic lung infections. J. Infect. Dis. 205:121-127.
35. Routh MD, Su CC, Zhang Q, Yu EW. 2009. Structures of AcrR and CmeR: insight into the mechanisms of transcriptional repression and multi-drug recognition in the TetR family of regulators. Biochim. Biophys. Acta 1794:844-851.
36. Sato H, Frank DW. 2004. ExoU is a potent intracellular phospholipase. Mol. Microbiol. 53:1279-1290.
37. Schumacher MA, et al. 2002. Structural basis for cooperative DNA binding by two dimers of the multidrug-binding protein QacR. EMBO J. 21: 1210-1218.
38. Shanks RM, Caiazza NC, Hinsa SM, Toutain CM, O'Toole GA. 2006. Saccharomyces cerevisiae-based molecular tool kit for manipulation of genes from gram-negative bacteria. Appl. Environ. Microbiol. 72:5027-5036.
39. Smith EE, et al. 2006. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl. Acad. Sci. U. S. A. 103: 8487-8492.
40. Su CC, Rutherford DJ, Yu EW. 2007. Characterization of the multidrug efflux regulator AcrR from Escherichia coli. Biochem. Biophys. Res. Commun. 361:85-90.
41. Williams BJ, Dehnbostel J, Blackwell TS. Pseudomonas aeruginosa: host defence in lung diseases. Respirology 15:1037-1056.
42. Ye S, MacEachran DP, Hamilton JW, O'Toole GA, Stanton BA. 2008. Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif. Am. J. Physiol. Cell Physiol. 295:C807-C818.
43. Yorgey P, Rahme LG, Tan MW, Ausubel FM. 2001. The roles of mucD and alginate in the virulence of Pseudomonas aeruginosa in plants, nematodes, and mice. Mol. Microbiol. 41:1063-1076.
44. Zhao WH, Hu ZQ. Beta-lactamases identified in clinical isolates of Pseudomonas aeruginosa. Crit. Rev. Microbiol. 36:245-258.